First-pass extracted concept

gene therapy in hemophilia

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

This review's aims are (1) to deconstruct gene therapy in hemophilia and provide a basic framework for understanding its components and processes, including the transgene, the vector, and the delivery systems...

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1availability statussupports2025Source 1DOI PubMed

Gene therapy for hemophilia is now commercially available for both hemophilia A and hemophilia B.

Claim 2clinical implementation scopesupports2025Source 1DOI PubMed

The review covers eligibility and exclusion criteria, expected outcomes, shared decision-making, and implementation in clinical practice for approved hemophilia gene therapies.

Claim 3complexity statementsupports2025Source 1DOI PubMed

Hemophilia gene therapy has complex biology, mechanisms, and administration logistics compared with other hemophilia treatments.

Claim 4development pipelinesupports2025Source 1DOI PubMed

Additional hemophilia gene therapy products using different approaches have entered clinical trials, with more in preclinical development.

Claim 5review scopesupports2025Source 1DOI PubMed

The review aims to provide a framework for understanding hemophilia gene therapy components and processes, including the transgene, vector, and delivery systems.